Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on blood testing & biomarkers. Browse all Blood Testing & Biomarkers education

A handful of genes show up again and again across seemingly unrelated autoimmune conditions, and PTPN22 is one of the most important. A single common variant in this gene has been linked to type 1 diabetes, rheumatoid arthritis, lupus, and several others — which raises an obvious question: how can one gene touch so many different diseases? The answer says a lot about how the immune system draws the line between friend and foe.

What the PTPN22 gene does

PTPN22 codes for a protein called lymphoid tyrosine phosphatase (LYP), a "brake" on immune-cell activation. LYP helps set the threshold for how easily T cells and B cells switch on. Set that threshold well, and your immune system responds to real threats while ignoring your own tissue. Alter it, and the balance between vigilance and tolerance can shift — which is the heart of autoimmunity.

The R620W (rs2476601) variant

The key variant is R620W (rs2476601), a single amino-acid change also written as C1858T. It changes how the LYP brake interacts with immune-signaling machinery, altering the activation threshold of immune cells. It is a common variant — carried by a meaningful share of people of European ancestry — which is exactly why it turns up across so many autoimmune association studies. It is not a rare mutation; it is a widespread tuning difference.

Which autoimmune conditions research links to PTPN22

The R620W variant has one of the broadest autoimmune association profiles of any gene. Research has connected it with increased risk for type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, Graves' disease, juvenile idiopathic arthritis, and vitiligo, among others. Crucially, "increased risk" means a shift in population-level odds — most carriers never develop any of these conditions, and many people with these conditions do not carry the variant.

Why one gene touches so many conditions

PTPN22's reach makes sense once you see what it regulates. Because it sets a general activation threshold rather than targeting one organ, a variant that nudges that threshold can subtly influence immune tolerance system-wide. Which condition, if any, emerges depends on countless other factors — additional genes, infections, hormones, and environment. This is the difference between a shared upstream susceptibility gene and a cause; PTPN22 is squarely the former.

What a PTPN22 result does and does not mean

Carrying the R620W variant is not a diagnosis and does not mean you will develop an autoimmune disease. Genetic testing cannot diagnose, predict, or rule out any of these conditions. What a variant does provide is context: a reason to be aware of family history, to recognize relevant symptoms early, and to have an informed conversation with a qualified provider who can order appropriate clinical evaluation. Diagnosis always belongs to a clinician, never to a genetic report.

What pathway-level genetic insight adds

Seeing your immune-regulation genetics in context helps you ask better questions rather than jump to conclusions. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in immune-signaling pathways such as PTPN22. It does not diagnose, treat, manage, or predict autoimmune disease — it delivers pathway-level educational context so you and your healthcare provider can factor your biology into a broader picture of family history, symptoms, and clinical testing.

Frequently Asked Questions

What autoimmune disorders are linked to PTPN22?

The PTPN22 R620W variant (rs2476601) is associated with increased risk for type 1 diabetes, rheumatoid arthritis, systemic lupus, Hashimoto's thyroiditis, Graves' disease, juvenile idiopathic arthritis, and vitiligo, among others. These are statistical associations across populations — most carriers never develop any of these conditions.

If I carry the PTPN22 variant, will I get an autoimmune disease?

No. Carrying the R620W variant shifts population-level odds but does not cause disease or predict it for any individual. Most carriers stay healthy, and many people with autoimmune conditions do not carry it. Genetics is one factor among genes, infections, hormones, and environment — not a verdict.

Can genetic testing diagnose an autoimmune condition?

No. Genetic testing cannot diagnose, predict, or rule out any autoimmune disease. It provides pathway-level context about immune-regulation variants like PTPN22. Diagnosis requires clinical evaluation — symptoms, exam, and specific lab work ordered and interpreted by a qualified healthcare provider, never a genetic report alone.

Genetics as a guide, not a guarantee. If you want to understand your own peptide-related pathways at the DNA level before your next conversation with a provider, the Precision Peptide Genetic Test maps the variants that shape your baseline biology — so you can test before you invest.

This article is part of the PlexusDx Education Hub. Browse all Blood Testing & Biomarkers education

Disclaimer: The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.